TSC2 Q1178*

CI-VAR-00003478Explore in graph →NP_000539.2:p.Gln1178TerNM_000548.4:c.3532C>TClinVar 49263 CIViC 469 rs45517297

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Thyroid Gland Carcinoma1
TSC2 Q1178*	Everolimus	Predictive	C	Supports Sensitivity Response	5	accepted	EID1108 In a phase II trial of everolimus in thyroid cancer (NCT00936858), seven patients with anaplastic thyroid carcinoma were treated, and only one patient achieved an objective response. This 57-year-old … (full text at CIViC) PMID 25295501 · Wagle et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
49263	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Tuberous sclerosis syndrome; Tuberous sclerosis 2	germline	4	Nov 23, 2022	clinvar